Aspirin in Acute Pneumonia in the Elderly: a Multicenter, Double-blind, Randomized, Placebo-controlled Trial.
Key facts
- Who runs it
- Centre Hospitalier Universitaire Dijon
- Where
- France15 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 600 people, planned
- Starts
- Jul 2028
- Expected to end
- Nov 2031
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Acetylsalicylic acid/Aspirin (100 mg)
- Placebo acetylsalicylic acid (100 mg) / 0.9% sodium chloride
- Record updated
- 24 September 2026
Who can take part
- Age
- 75 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 38 criteriaShow less
Who can take part
- Informed consent obtained from patient or relative/trusted person if patient unable to consent
- Age ≥75 years
- Clinical diagnosis of AP, presumed to be of bacterial or viral origin, with at least two of the following signs or symptoms:
- cough,
- purulent expectoration,
- thoracic pain,
- dyspnea/tachypnea,
- temperature > 37.8°C or < 36°C,
- unilateral crackles
- Patient hospitalized for at least 48 hours
- Onset of clinical signs < 7 days
- New radiological infiltrate documented by X-ray, ultrasound or CT scan
Who cannot take part
- Patient with at least 3 episodes of inhalation pneumonitis in the 12 months prior to inclusion
- Antiplatelet therapy
- Steroidal or non-steroidal anti-inflammatory treatment or oral corticosteroids without proton pump inhibitor (PPI)
- Treatment with methotrexate (>20 mg per week), anagrelide, probenecid, nicorandil, defibrotide
- Hypersensitivity to acetylsalicylic acid or to any of the excipients of the investigational drug or placebo
- Previous gastrointestinal hemorrhage
- Pre-acute episode swallowing disorders impairing oral medication intake
- Dyspepsia or gastroesophageal reflux disease (GERD) without PPI use
- History of asthma induced by the administration of salicylates or non-steroidal anti-inflammatory drugs
- Active peptic ulcer disease or history of recurrent peptic ulcer disease
- History of cerebrovascular haemorrhage
- Known hereditary or acquired coagulation disorder
- Acute kidney injury (clairance < 15 ml/min selon MDRD - Modification of Diet in Renal Disease),
- Severe uncontrolled heart failure
- Persistente severe hypertension (PAS > 180mmHg)
- History of hemorrhage with Hemoglobin > 3g /dl requiring transfusion, vasoactive treatment or surgery
- Thrombocytopenia (platelets < 50 giga/L)
- Liver cirrhosis or acute liver failure (PTT<50%),
- Mechanically ventilated pneumonia
- Documented SARS CoV2 pneumonia
- Physician-assessed life expectancy < 90 days
- Anticoagulant treatment (curative doses)
- Contraindications to aspirin (preventive doses) or its placebo at the time of inclusion:
- Patient with mastocytosis
- Person not affiliated to a national social security scheme
- Patient under court protection
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Acute pneumonia is a very common disease, and one of the leading causes of hospitalization and death in France. Almost a century after the discovery of penicillin, no major breakthrough has significantly reduced pneumonia-related mortality. While the choice of an appropriate antibiotic is decisive in the acute phase of the disease, the longer-term prognosis depends essentially on the worsening of other underlying pathologies, particularly in the elderly. In cured patients, excess mortality persists several months after the episode of pneumonia, due in particular to the onset of cardiovascular complications. Recent scientific literature shows an association between the prescription of cardio-protective drugs and survival after pneumonia. Older patients are usually excluded from interventional studies, so there are no specific recommendations for these patients at high risk of both acute pneumonia and cardiovascular events.
Read full original descriptionShow less
The aim of this study is to assess the efficacy of low-dose aspirin therapy after pneumonia in preventing cardiovascular events in the elderly.
The main objective is therefore to evaluate the impact of aspirin at a dose of 100mg per day on all-cause mortality at 90 days in patients over 75 years of age hospitalized for pneumonia.
The 2 groups in the trial
- ExperimentalTreatment being tested
Treatment: Acetylsalicylic acid/Aspirin (100 mg)
- ControlPlacebo, for comparison
Treatment: Placebo acetylsalicylic acid (100 mg) / 0.9% sodium chloride
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 24 September 2026